4Q17

Tianjin Zhongxin Pharma on its way to a stellar 2018 & beyond, says UOB

SINGAPORE (Apr 2): UOB Kay Hian is keeping Tianjin Zhongxin Pharmaceutical Group at “buy” with a higher target price of US$1.66 ($2.17), pegged to peer average of 14.1 times FY18 earnings.

This comes after Tianjin Zhongxin Pharma exceeded expectations in 4Q17 due to a net profit surge, bringing full-year PATMI to RMB473.3 million, 4.5% above UOB’s full-year forecast on higher 4Q blended gross margin after factoring in a price hike for the group’s key product, “Su Xiao Jiu Xin” pills.

Vard sees 4Q losses double to NOK 131 mil on lower margins after reassessment

SINGAPORE (Mar 1): Vard Holdings reported a doubling of 4Q17 losses to NOK 131 million ($22.2 million) from its net loss position of NOK 67 million a year ago.

The group mainly attributes this to a reassessment of its net realizable value (NRV) of vessels held in inventory which resulted in a lower EBDITA margin.

This resulted in EBITDA falling to NOK 8 million in 4Q, down from NOK 67 million in the corresponding period. Excluding the effects of the reassessment, EBITDA before restructuring costs would have been NOK 62 million for 4Q17, in line with a year ago.

Wee Hur 4Q earnings triple to $7.8 mil on higher revenue

SINGAPORE (Mar 1): Property developer Wee Hur Holdings saw earnings more than triple to $7.8 million in 4Q17 from $2.2 million in 4Q16 on the back of higher revenue.

Revenue for the quarter grew 11% to $40.5 million in 4Q17 from $36.6 million in 4Q16 due to higher contributions from on-going construction projects.

The group also saw higher cost savings in terms general & administrative expenses, marketing & distribution costs, and finance costs after finalising accounts of some its completed construction projects.

Starburst swings back into the black with FY17 earnings of $0.1 mil

SINGAPORE (Mar 1): Starburst Holdings, the firearms-training facilities provider, swung back into profitability in FY17 with earnings of $0.1 million compared to a loss of $11.7 million in FY16.

This was due to improved margins and a significant decline in project and production costs.

Revenue declined 13.3% to $15.9 million in FY17 from $18.3 million in FY16, due to the lower contributions from projects undertaken in the full year under review.

Hotel Royal posts 92.5% drop in 4Q earnings to $0.2 mil on higher operating expenses

SINGAPORE (Mar 1): Hotel Royal posted a 92.5% decline in fourth quarter earnings to $0.2 million in 4Q17 compared to its earnings of $2.9 million in 4Q16 on the back of higher operating expenses.

Revenue for quarter grew by 2.6% to $15.5 million from $15.1 million previously, due to higher room revenue and higher food & beverage revenue in Hotel Royal Bangkok @ Chinatown.

Cost of sales however grew 28.4% to $9.4 million from $7.3 million previously due to higher costs in Hotel Royal Bangkok @ Chinatown.

Yongnam FY17 losses cut by half to $15.8 mil on improved project margins

SINGAPORE (Mar 1): Yongnam Holdings reported full-year losses narrowed by half to $15.8 million in FY17 from $31.6 million in FY16 on improved margins for some of its projects.  

Revenue for the full year fell 4.6% to $306.7 million in FY17 from $321.4 million in FY16 due to lower contributions from its structural steelworks and mechanical engineering businesses, which more than offset the increase in revenue contributions from its specialist civil engineering segment.

More acquisitions likely for Singapore Medical Group in 2018

SINGAPORE (Mar 1): UOB Kay Hian is maintaining its “buy” call on Singapore Medical Group (SMG) with a P/E-based target price of 83 cents, pegged to the peer average FY18 P/E ratio of 26.8 times.

In a Thursday report, analyst Nicholas Leow highlights that the group’s 4Q17 results announced yesterday were in line with UOB’s estimates with FY17 earnings more than trebling to $8.5 mil due to earnings-accretive acquisitions made during the year – which in turn added other disciplines to the SMG specialist verticals.

Outlook remains stable for Asian Pay Television Trust, says Phillip

SINGAPORE (Mar 1): Phillip Capital is maintaining “accumulate” on Asian Pay Television Trust (APTV) with a lower target price of 62 cents from 64 cents previously to account for lower ARPU and higher cash taxes in FY18.

This comes after the group’s 4Q17 revenue and EBITDA came in line with expectations, although Cable TV average revenue per user (ARPU) was softer than expected in 4Q, Phillip’s head of research Paul Chew attributes to customers taking advantage of a discount offered by pre-paying their three-month bundles over the period.

Will FY18 be another record year for UMS Holdings?

SINGAPORE (Mar 1): DBS and CIMB are positive on the outlook of UMS Holdings, maintaining their respective “buy” calls with higher target prices after the group delivered record 4Q profits on higher revenue and a one-off gain.

See: UMS Holdings' 4Q17 earnings treble to $15.8 mil on higher revenue & one-off gain

Fu Yu Corp announces 56.8% lower 4Q earnings of $2.4 mil on other operating expenses

SINGAPORE (Feb 28): Fu Yu Corporation posted 4Q17 earnings of $2.4 million for the 4Q ended Dec 2017, 56.8% down from $5.6 million a year ago on other operating expenses.

Revenue for the quarter grew 8.7% to $52.7 million from $48.5 million, buoyed by higher sales across its operations in Singapore, Malaysia and China.

Gross profit margin expanded to 19.1% compared to 17.3% in 4Q16.

Be informed of the stories that matter

Subscribe

Be informed of the stories that matter